Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
ProAssurance Corporation ( PRA - Analyst Report ) reported second-quarter operating earnings per share of $1.92, striding ahead of the Zacks Consensus Estimate of $1.52 and the year-ago quarter’s earnings of $1.74. Operating earnings stood at $59.5 million, compared with $53.7 million in the prior-year quarter.
Operating income excludes the effects of net realized investment gains or losses and guaranty fund assessments or recoupments. The positive adjustment to net income was 3 cents per share compared to a negative adjustment of 5 cents in the year-ago quarter.
Including non-recurring items, net income was reported at $58.5 million or $1.89 per share, compared with $55.1 million or $1.79 per share in the year-ago quarter.
During the quarter under review, total revenue of ProAssurance declined to $163.9 million from $174.8 million in the year-ago quarter. Revenue also lagged the Zacks Consensus Estimate of $179 million.
The decline in revenue was largely attributable to an 11.4% year over year fall in gross premiums written to $102.2 million. Moreover, owing to the lower loss severity, arising from accident years 2004 to 2009, the company garnered $60 million of net favorable loss reserve development in the reported quarter versus $50 million a year ago.
Net investment income in the quarter was $34.5 million, declining 5% from $36.3 million in the prior-year quarter. Net investment result (sum of net investment income and equity in earnings of unconsolidated subsidiaries) amounted to $32.3 million, decreasing 5% from $33.9 million in the year-ago quarter. However, net realized investment loss was $1.5 million in the reported quarter as against net realized investment gains of $2.2 million in the second-quarter of 2011.
Financial Position
ProAssurance generated net cash flow from operating activities of $4.6 million in the reported quarter, declining from $28.2 million in the prior-year quarter. Total assets of the company at the end of the quarter were $5.0 billion, at par with December 31, 2011, while shareholders’ equity was $2.28 billion, reflecting a 2.8% increase from $2.16 billion as of December 31, 2011. Book value per share also hiked 4.9% to $74.30 from $70.84 as on December 31, 2011.
Financial Ratios
ProAssurance’s net loss ratio for the reported quarter came in at 36.6%, compared with 47.0% in the prior-year quarter. Additionally, expense ratio deteriorated to 26.8% from 24.0% in the prior-year quarter.
The combined ratio improved to 63.4% from 71.0% in the comparable quarter last year, while operating ratio contracted 740 basis points to 37.1% from 44.5% in the prior-year quarter. Return on equity (ROE) for the reported quarter was 10.4%, down from 11.4% in the second quarter of 2011.
Debt Repayment Update
In June 2012, ProAssurance decide to repay long-term debt worth $35 million during the third quarter of 2012. Additionally, in July 2012, the company repaid $17 million worth of notes payable and terminated a related interest rate swap, which led to a loss of $2.5 million. This loss will be recognized in the third quarter of 2012.
Share Repurchase Update
ProAssurance did not undertake a share repurchase activity in the reported quarter. The company has approximately $188 million left under its $200 million authorization granted by the board in November 2010. ProAssurance has been purchasing shares in the open market since 2005 and has repurchased 6.1 million shares for $321 million to date.
Dividend Update
Consistent with the company’s dividend policy, ProAssurance paid a quarterly cash dividend of 25 cents per share in July 2012.
Peer Comparison
ProAssurance’s rival Greenlight Capital Re, Ltd. ( GLRE - Snapshot Report ) reported its second-quarter operating loss of 98 cents per share, better than the Zacks Consensus Estimate of a loss of $1.05. However, the results compared unfavorably with loss per share of 44 cents in the year-ago quarter.
Zacks Rank
We retain our long term ‘Outperform’ recommendation on ProAssurance. Currently, it carries a Zacks #1 Rank, implying a short-term ‘Strong Buy’ rating.
Read the full reports :
Analyst Report on PRA
Snapshot Report on GLRE